BMS Study Invention definition

BMS Study Invention means any Invention to the extent specifically relating to the BMS Study Drug (including compositions of matter or formulations of the BMS Study Drug and methods of use or manufacture of the BMS Study Drug as a monotherapy) and not relating to the Recipient Study Drug or the Combined Therapy.

BMS Study Invention means any Invention that pertains to (a) the composition of matter of any BMS Class Drug (and not any Recipient Class Drug), (b) method of manufacture or formulation of any BMS Class Drug (and not any Recipient Class Drug) as a Single Agent Compound, and/or (c) a method of use of any BMS Class Drug (and not any Recipient Class Drug) as a monotherapy or as used with other agents, antibodies or compounds (other than an Invention pertaining, whether generically or specifically, to the composition of matter, method of manufacture or formulation, or a method of use of both a BMS Class Drug and a Recipient Class Drug).

BMS Study Invention means any Invention that pertains solely to (a) the composition of matter of any BMS Class Drug (and not any Recipient Class Drug), (b) method of manufacture or formulation of any BMS Class Drug (and not any Recipient Class Drug) as a Single Agent Compound, and/or (c) a method of use of any BMS Class Drug (and not any Recipient Class Drug) as a monotherapy or as used with other agents, antibodies or compounds (other than an Invention pertaining, whether generically or specifically, to the composition of matter, method of manufacture or formulation, or a method of use of both a BMS Class Drug and a Recipient Class Drug).

Examples of BMS Study Invention in a sentence

• Notwithstanding any other provision of this Agreement to the contrary, neither Party shall file any patent application claiming: (i) both a BMS Study Invention and a Recipient Study Invention; (ii) both a BMS Study Invention and a Combined Therapy Invention; or (iii) both a Recipient Study Invention and a Combined Therapy Invention; in each case, without the prior written consent of the other Party, which the other Party may withhold in its sole discretion.

• Please note the pages of your One Stop Operating Budget in your final document.The One Stop Operating Budget developed with the Infrastructure Funding Agreement template is included as an attachment on pages .Cost Reconciliation and AllocationAll Parties agree that a quarterly reconciliation of budgeted and actual costs and update of the allocation bases will be completed in accordance with the following process:1.

• The reviewing Party shall determine whether any of its Confidential Information that is contained in such proposed disclosure, publication or presentation should be modified or deleted, whether to file a patent application on any Recipient Study Invention (solely with respect to the Recipient) or BMS Study Invention (solely with respect to BMS) or Combined Therapy Invention disclosed therein.

More Definitions of BMS Study Invention

BMS Study Invention means any Invention that relates to: (a) the composition of matter of the BMS Compound (and not the Five Prime Compound); (b) method of manufacture or formulation of the BMS Compound (and not the Five Prime Compound) as a single agent; (c) a method of use of the BMS Compound (and not the Five Prime Compound) as a monotherapy or as used with agents, antibodies or compounds other than an Invention comprising, whether generically or specifically, the use of both the BMS Compound (and/or any other antibodies that are designed to selectively bind to PD-1) and a Five Prime Compound (and/or any other antibodies that are designed to selectively bind to CSF1R)); or (d) arising from the development of the Dako Assay.

BMS Study Invention means any Invention to the extent specifically relating to the BMS Compound (including compositions of matter or formulations of the BMS Compound and methods of use or manufacture of the BMS Compound as a monotherapy) and [***].

BMS Study Invention means any Study Invention that pertains to: (a) the composition of matter of the BMS Study Drug (and not the Recipient Study Drug), (b) a method of manufacture or formulation or administration, including dosing, of the BMS Study Drug (and not the Recipient Study Drug) as a Single Agent Compound (and for clarity, not with respect to the Combined Therapy), and/or (c) a method of use of the BMS Study Drug (and not the Recipient Study Drug) as a monotherapy or as used with other agents, antibodies or compounds (other than a Study Invention pertaining to use with the Recipient Study Drug).

BMS Study Invention means any Invention (a) specifically relating to the BMS Compound or other anti-PD-1 antibodies (including compositions of matter or formulations of the BMS Compound or other anti-PD-1 antibodies, and methods of use or manufacture of the BMS Compound or other anti-PD-1 antibodies, as a monotherapy) and not relating to the Compugen Compound or the Combined Therapy or any other therapeutic agent and/or (b) arising from the PD-L1 Expression Testing of Samples (including Inventions based on the results of PD-L1 Expression Testing of Samples) and not relating to the Compugen Compound or the Combined Therapy or any other therapeutic agent (other than the BMS Compound).

BMS Study Invention means any invention or Technology that would be a Collaboration Invention (except for the exclusion set forth therein) and that relates to (a) the composition of matter of the BMS Compound (and not the Nektar Compound), (b) method of Clinical Trial Collaboration Agreement_Nektar_BMS_September 2016 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 manufacture or formulation of the BMS Compound (and not the Nektar Compound) as a single agent, and/or (c) a method of use of the BMS Compound (and not the Nektar Compound) as a monotherapy or as used with agents, antibodies or compounds (other than a Collaboration Invention comprising, whether generically or specifically, the use of both the BMS Compound (and/or any other antibodies that are designed to selectively bind to PD-1 or PD-L1) and a Nektar Compound (and/or any other IL2-based CD122 agonist)).